These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1414 related articles for article (PubMed ID: 33733663)

  • 1. COVID-19 vaccines for low- and middle-income countries.
    Choi EM
    Trans R Soc Trop Med Hyg; 2021 May; 115(5):447-456. PubMed ID: 33733663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.
    Nhamo G; Chikodzi D; Kunene HP; Mashula N
    Glob Public Health; 2021 Mar; 16(3):319-339. PubMed ID: 33317389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming COVID-19 vaccines into vaccination : Challenges and opportunities for management scientists.
    Dai T; Song JS
    Health Care Manag Sci; 2021 Sep; 24(3):455-459. PubMed ID: 34132977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for COVID-19: Where do we stand in 2021?
    Sharma K; Koirala A; Nicolopoulos K; Chiu C; Wood N; Britton PN
    Paediatr Respir Rev; 2021 Sep; 39():22-31. PubMed ID: 34362666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
    Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members
    Lancet; 2021 Feb; 397(10274):562-564. PubMed ID: 33516284
    [No Abstract]   [Full Text] [Related]  

  • 9. Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa.
    Rogers AB; Barrie MB; Fallah MP; Kelly JD
    Am J Trop Med Hyg; 2021 Jun; 105(2):278-280. PubMed ID: 34181573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
    Khan M; Adil SF; Alkhathlan HZ; Tahir MN; Saif S; Khan M; Khan ST
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
    Forman R; Shah S; Jeurissen P; Jit M; Mossialos E
    Health Policy; 2021 May; 125(5):553-567. PubMed ID: 33820678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead.
    Massinga Loembé M; Nkengasong JN
    Immunity; 2021 Jul; 54(7):1353-1362. PubMed ID: 34260880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why a pioneering plan to distribute COVID vaccines equitably must succeed.
    Nature; 2021 Jan; 589(7841):170. PubMed ID: 33442047
    [No Abstract]   [Full Text] [Related]  

  • 15. The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World.
    Jhaveri R
    Clin Ther; 2021 Apr; 43(4):702-710. PubMed ID: 33832783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variants of SARS-CoV-2 and the challenges of vaccines.
    Han X; Ye Q
    J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus disease 2019 (COVID-19) vaccines: A concise review.
    Samaranayake LP; Seneviratne CJ; Fakhruddin KS
    Oral Dis; 2022 Nov; 28 Suppl 2():2326-2336. PubMed ID: 33991381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.
    Li CX; Noreen S; Zhang LX; Saeed M; Wu PF; Ijaz M; Dai DF; Maqbool I; Madni A; Akram F; Naveed M; Li JH
    Biomed Pharmacother; 2022 Feb; 146():112550. PubMed ID: 34959116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.